{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/precision-medicines-neurodegenerative-disorders-optimizing-clinical-development#webpage",
"url": "https://www.fortrea.com/insights/precision-medicines-neurodegenerative-disorders-optimizing-clinical-development",
"name": "Precision medicines for neurodegenerative disorders: optimizing clinical development",
"description": "Explore this Fortrea white paper on optimizing clinical development for neurodegenerative disorders and discover how precision medicine, biomarker-driven research, and translational neuroscience strategies are shaping the future of neurology clinical development. The white paper examines the role of biomarkers for neurodegenerative diseases, patient stratification approaches, advanced therapies including gene and RNA therapeutics, and innovative neurology clinical trial methodologies designed to improve development efficiency and decision-making. Learn how translational neuroscience research, adaptive neurology trial design, biomarker-based patient enrollment, and patient-centric operational strategies are helping accelerate neurological drug development, improve targeting of complex neurological disorders, and support more effective execution of neurodegenerative clinical research programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Precision medicines for neurodegenerative disorders: optimizing clinical development",
"item": "https://www.fortrea.com/insights/precision-medicines-neurodegenerative-disorders-optimizing-clinical-development"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/precision-medicines-neurodegenerative-disorders-optimizing-clinical-development#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/precision-medicines-neurodegenerative-disorders-optimizing-clinical-development#webpage"
},
"headline": "Neurodegenerative Disorder Clinical Development & Biomarker Strategies | Fortrea White Paper",
"description": "Explore this Fortrea white paper on optimizing clinical development for neurodegenerative disorders and discover how precision medicine, biomarker-driven research, and translational neuroscience strategies are shaping the future of neurology clinical development. The white paper examines the role of biomarkers for neurodegenerative diseases, patient stratification approaches, advanced therapies including gene and RNA therapeutics, and innovative neurology clinical trial methodologies designed to improve development efficiency and decision-making. Learn how translational neuroscience research, adaptive neurology trial design, biomarker-based patient enrollment, and patient-centric operational strategies are helping accelerate neurological drug development, improve targeting of complex neurological disorders, and support more effective execution of neurodegenerative clinical research programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/optimizing-clinical%20development.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-15",
"dateModified": "2025-02-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/optimizing-clinical%20development.pdf",
"encodingFormat": "application/pdf"
}
}
]
}